Revenue (Notes)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

Revenue

    Our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions and Critical Care. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.

    Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end-customers at prices determined under a contract between us and the end-customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts in order to determine the transaction price, we use information available at the time, including our historical experience.

    We also warranty products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.

Revenue disaggregated

    The following table represents our revenues disaggregated by geography (in thousands):

	For the three months ended March 31,
Geography	2021		2020
Europe, the Middle East and Africa	$	34,800	$	37,928
Other Foreign	55,895		60,521
Total Foreign	90,695		98,449
United States	227,351		230,158
Total Revenues	$	318,046	$	328,607

    The following table represents our revenues disaggregated by product (in thousands):

	For the three months ended March 31,
Product line	2021		2020
Infusion Consumables	$	126,370	$	123,507
Infusion Systems	84,334		88,380
IV Solutions	94,176		104,291
Critical Care	13,166		12,429
Total Revenues	$	318,046	$	328,607

Contract balances

    The following table presents our changes in the contract balances for the three months ended March 31, 2021 and 2020 (in thousands):

	Contract Liabilities
Beginning balance, January 1, 2021	$	(6,430)
Equipment revenue recognized	461
Equipment revenue deferred due to implementation	(2,921)
Software revenue recognized	1,796
Software revenue deferred due to implementation	(1,794)
Ending balance, March 31, 2021	$	(8,888)
Beginning balance, January 1, 2020	$	(4,855)
Equipment revenue recognized	1,802
Equipment revenue deferred due to implementation	(3,990)
Software revenue recognized	1,235
Software revenue deferred due to implementation	(2,664)
Ending balance, March 31, 2020	$	(8,472)

    As of March 31, 2021, revenue from remaining performance obligations related to implementation of software and equipment is $7.3 million. We expect to recognize substantially all of this revenue within the next three to six months dependent on implementation restrictions due to the novel coronavirus and its variants ("COVID-19"). Revenue from remaining performance obligations related to annual software licenses is $1.5 million. We expect to recognize substantially all of this revenue over the next twelve months.